当地时间6月26~29日，2024 ESMO Gastrointestinal Cancers Annual Congress，即2024 ESMO胃肠道肿瘤年会（简称2024 ESMO GI）即将在德国慕尼黑拉开序幕，同步线上直播。ESMO胃肠道肿瘤年会是全球胃肠道肿瘤学界展示胃肠道肿瘤学领域有影响力、高质量新研究数据的平台，大会为国际交流提供了极佳机会。多项研究入选LBA、Proffered Paper和mini oral。近日ESMO官网已公布研究标题。【肿瘤资讯】特此整理重磅口头报告标题，以飨读者。
Late-breaking abstracts (LBA)
LBA1 - Pembrolizumab in combination with xelox and bevacizumab in patients with microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC) and a high immune infiltrate: a proof of concept study. Preliminary results of FFCD 1703 POCHI trial
中文标题：帕博利珠单抗联合xelox和贝伐珠单抗治疗微卫星稳定（pMMR/MSS）转移性结直肠癌（mCRC）和高免疫浸润患者：一项概念验证性研究，即FFCD 1703 POCHI试验的初步结果
讲者：David Tougeron (Poitiers, 法国)
LBA2 - Efficacy interim analysis of REGINA, a phase II trial of neoadjuvant regorafenib (Rego), nivolumab (Nivo), and short-course radiotherapy (SCRT) in stage II-III rectal cancer (RC)
中文标题：REGINA研究疗效的中期分析：瑞戈非尼、纳武利尤单抗和短程放疗（SCRT）新辅助治疗II-III期直肠癌的2期试验
讲者：Francesco Sclafani (Anderlecht, 比利时)
LBA3 - Final analysis of the phase 3 KEYNOTE-585 study of pembrolizumab plus chemotherapy vs chemotherapy as perioperative therapy in locally-advanced gastric and gastroesophageal junction cancer
中文标题：3期KEYNOTE-585研究的最终分析：帕博利珠单抗联合化疗 vs 化疗围手术期治疗局部晚期胃/胃食管结合部癌
讲者：Kohei Shitara (Kashiwa, 日本)
LBA4 - Switch maintenance with ramucirumab plus paclitaxel versus continuation of oxaliplatin-based chemotherapy in advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer: Final results and key biomarkers of the ARMANI phase 3 trial
中文标题：雷莫西尤单抗+紫杉醇转换维持治疗 vs 继续以奥沙利铂为基础的化疗方案用于HER2阴性晚期胃/胃食管结合部癌患者：ARMANI 3期试验的最终结果和关键生物标志物
讲者：Giovanni Randon (Milan, Italy)
Proffered Paper (plenary) session
1O - Chemotherapy and Liver Transplantation versus Chemotherapy alone in patients with definitively unresectable colorectal liver metastases: Updated results from the randomized TRANSMET trial
中文标题：化疗+肝移植 vs 单纯化疗用于结直肠癌肝转移患者：TRANSMET随机试验的最新结果
讲者：Maximiliano Gelli (Villejuif, 法国)
2O - Health-related quality of life (HRQoL) with first-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW
中文标题：纳武利尤单抗+伊匹木单抗 vs 化疗一线治疗微卫星高度不稳定(MSI-H)/错配修复缺陷(dMMR)转移性结直肠癌(mCRC)患者的健康相关生活质量(HRQoL)：CheckMate 8HW
讲者：Sara Lonardi (Padova, 意大利)
3O - PRODIGE 68 - UCGI 38 - SOREGATT: A randomized phase 2 study comparing the sequences of regorafenib (reg) and trifluridine/tipiracil (t/t) after failure of standard therapies in patients (pts) with metastatic colorectal cancer (mCRC)
中文标题：PRODIGE 68 - UCGI 38 - SOREGATT：比较在标准治疗失败后使用瑞戈非尼和曲氟尿苷替匹嘧啶治疗转移性结直肠癌（mCRC）患者的不同用药顺序的随机2期研究
讲者：Michel P. Ducreux (Villejuif, 法国)
Mini Oral session 1
4MO - Is it time for a new staging system for colon adenocarcinoma (CA)?
中文标题：是否是时候为结肠腺癌（CA）制定新的分期系统了？
讲者：N. Arvind Dasari (Houston, 美国)
6MO - Evaluation of plasma assessed comprehensive genomic profiling before first line treatment with FOLFIRI plus cetuximab in RAS/BRAF V600E wild type metastatic colorectal cancer patients in the CAPRI 2-GOIM trial
中文标题：CAPRI 2-GOIM试验：使用FOLFIRI+西妥昔单抗一线治疗RAS/BRAF V600E野生型转移性结直肠癌患者前的全基因组分析评估
讲者：Giulia Martini (Napoli, 意大利)
5MO - Individual patient data (IPD) meta-analysis of randomised phase III trials (RP3) of chemotherapy for resectable colorectal cancer liver metastases (CRCLM): EORTC RP-2145
中文标题：化疗治疗可切除结直肠癌肝转移(CRCLM)的随机III期试验(RP3)的个体患者数据(IPD)荟萃分析：EORTC RP-2145
讲者：Giacomo Bregni (Anderlecht, 比利时)
504MO - Phase 1 Study of the PKMYT1 Inhibitor Lunresertib (Lunre) in Combination with FOLFIRI in Advanced Gastrointestinal (GI) Cancers (MINOTAUR Study)
中文标题：PKMYT1抑制剂Lunresertib (Lunre)联合FOLFIRI治疗晚期胃肠道肿瘤的1期研究(MINOTAUR研究)
讲者：Elisa Fontana (英国伦敦)
165MO - Early detection of HCC by routine blood based-AI
中文标题：基于血常规的AI技术早期检测HCC
讲者：Kin Nam Kwok (Kowloon, 中国香港特别行政区)
211MO - First-Line Efficacy of [177Lu]Lu-DOTA-TATE in Patients with Advanced Grade 2 and Grade 3, Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors by Tumor Grade and Primary Origin: Subgroup Analysis of the Phase 3 NETTER-2 Study
中文标题：[177Lu]Lu-DOTA-TATE一线治疗晚期2级和3级、分化良好的胃肠胰神经内分泌肿瘤患者的疗效：3期NETTER-2研究的亚组分析
讲者：Simron Singh (新加坡)
Mini Oral session 2
242MO - Neoadjuvant nivolumab plus ipilimumab in microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) rectal tumors: ECOG-ACRIN EA2201
中文标题：纳武利尤单抗联合伊匹木单抗新辅助治疗微卫星高度不稳定(MSI-H)/错配修复缺陷(dMMR)直肠癌：ECOG-ACRIN EA2201
讲者：Kristen K. Ciombor (Nashville, 美国)
7MO - Combined analyses of ctDNA and Immunoscore in stage III colon cancer patients: a post hoc analysis of the IDEA-France and -Greece trials
中文标题：结合ctDNA和免疫评分对III期结肠癌患者进行综合分析：法国和希腊IDEA试验的事后分析
讲者：Julien Taieb (法国巴黎)
8MO - Neoadjuvant botensilimab (BOT) plus balstilimab (BAL) in resectable mismatch repair proficient and deficient colorectal cancer: NEST-1 clinical trial
中文标题：bottensilimab (BOT)联合balstilimab (BAL)新辅助治疗可切除错配修复正常和缺陷的结直肠癌：NEST-1临床试验
讲者：Pashtoon M. Kasi (美国纽约)
Mini Oral session 3
279MO - Three-year survival, safety and extended long-term survivor (eLTS) analysis from the Phase 3 TOPAZ-1 study of durvalumab (D) plus chemotherapy in biliary tract cancer (BTC)
中文标题：度伐利尤单抗+化疗一线治疗胆道恶性肿瘤(BTC)的3期TOPAZ-1研究的3年生存率、安全性和扩展长期生存(eLTS)分析结果
讲者：Do-Youn Oh (韩国首尔)
280MO - CD40 agonist mitazalimab combined with mFOLFIRINOX (mFFX) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Primary analysis of the OPTIMIZE-1 phase 1b/2 study
中文标题：CD40激动剂mitazalimab联合mFOLFIRINOX(mFFX)治疗转移性胰腺导管腺癌(mPDAC)：OPTIMIZE-1 1b/2期研究的初步分析结果
讲者：Teresa Macarulla Mercade (西班牙巴塞罗那)
395MO - Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in advanced or metastatic esophageal squamous cell carcinoma (ESCC): PD-L1 biomarker analysis from RATIONALE-306
中文标题：替雷利珠单抗(TIS)+化疗(CT) vs 安慰剂(PBO)+化疗(CT) 一线治疗晚期/转移性食管鳞癌(ESCC)：RATIONALE-306研究中的PD-L1生物标志物分析
讲者：Eric Raymond (法国巴黎)
396MO - Anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate (ADC) IBI343 in patients (pts) with solid tumors and gastric/gastro-esophageal junction adenocarcinoma (G/GEJ AC): A phase 1 study
中文标题：靶向Claudin 18.2(CLDN18.2)的抗体药物偶联物(ADC)IBI343治疗实体瘤和胃/胃食管结合部腺癌患者：一项1期研究
讲者：Jia Jenny Liu (Darlinghurst, 澳大利亚)
397MO - Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in HER2-negative advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma (GC/GEJC): PD-L1 biomarker analysis from RATIONALE-305
中文标题：替雷利珠单抗(TIS)联合化疗(CT) vs 安慰剂(PBO)联合化疗(CT)一线治疗HER2阴性晚期或转移性胃/胃食管结合部腺癌患者：RATIONALE-305研究中的PD-L1生物标志物分析
讲者：Markus Moehler (Mainz, 德国)
排版编辑：肿瘤资讯-AS
点击下方图片关注【2024 ESMO GI】专栏，及时查看最新国际大会资讯！
本文专供医学专业人士参考，未经著作人许可，不可出版发行。同时，欢迎个人转发分享，其他任何媒体、网站如需转载或引用本网版权所有内容，须获得授权，且在醒目位置处注明“转自：良医汇-肿瘤医生APP”。
苏公网安备32059002004080号
